Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Completed · Phase 1
Conditions studied: Solid Tumor, Unspecified, Adult
In brief
This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.
Key facts
- Study ID
- NCT03318445
- Run by
- Pamela Munster
- People needed
- 22
- Starts
- 2018-01-12
- Expected to finish
- 2021-03-01
- Last updated by the study team
- 2021-03-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California San Francisco — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.